Wedbush Research Analysts Reduce Earnings Estimates for KNSA

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Stock analysts at Wedbush cut their FY2024 EPS estimates for Kiniksa Pharmaceuticals in a report released on Tuesday, October 29th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.42) per share for the year, down from their previous estimate of ($0.16). Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.29) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.49 EPS, FY2026 earnings at $1.08 EPS and FY2027 earnings at $1.47 EPS.

Several other brokerages also recently commented on KNSA. Evercore ISI increased their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday. Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $34.60.

Kiniksa Pharmaceuticals Stock Down 1.8 %

Shares of KNSA opened at $22.59 on Thursday. Kiniksa Pharmaceuticals has a 12-month low of $14.12 and a 12-month high of $28.15. The stock has a market cap of $1.61 billion, a P/E ratio of -140.81 and a beta of 0.33. The business’s fifty day moving average is $25.57 and its 200 day moving average is $22.42.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm’s revenue was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.20) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KNSA. Allspring Global Investments Holdings LLC grew its stake in Kiniksa Pharmaceuticals by 18.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 61,106 shares of the company’s stock valued at $1,206,000 after acquiring an additional 9,490 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Kiniksa Pharmaceuticals by 42.7% during the 1st quarter. Principal Financial Group Inc. now owns 58,991 shares of the company’s stock valued at $1,164,000 after purchasing an additional 17,659 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Kiniksa Pharmaceuticals by 5.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock worth $413,000 after purchasing an additional 1,153 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Kiniksa Pharmaceuticals by 7.8% in the first quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company’s stock worth $530,000 after buying an additional 1,940 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals during the first quarter valued at $3,107,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares in the company, valued at approximately $1,359,232.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 17,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,692 shares of company stock worth $2,950,315. Company insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.